Antihemophilic factor (recombinant)

(Advate®)

Antihemophilic factor (recombinant)

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormInjection (intravenous; 250, 500, 1000, 1500, 2000, 3000 or 4000 IU)
Drug ClassRecombinant antihemophilic factors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for use in children and adults with hemophilia A for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Antihemophilic factor (recombinant) (Advate) is indicated for use in children and adults with hemophilia A, where it aids in the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
  • Six studies provided a comparison between Advate and other drugs used for managing Hemophilia A.
  • Prophylactic treatment using antihemophilic factor (recombinant) significantly lowers both annualized bleeding rate and joint bleeding rate compared to episodic treatment across all dosages - low, intermediate, or high.
  • The effectiveness of different prophylactic clotting factor concentrate regimens showed no discernable difference in joint bleeding outcomes among various dosing strategies; however, they did show an improvement in reducing total bleed events.
  • Comparative analyses suggest that Advate has similar efficacy as other recombinant FVIII products but potentially greater efficiency due to lower annual consumption than rVIII-SingleChain.
  • Emicizumab was found to have a lower rate of treated bleeds when compared with FVIII prophylaxis, including Advate, suggesting superior efficacy within certain patient subgroups such as those without inhibitors.

Product Monograph / Prescribing Information

Document TitleYearSource
Advate (antihemophilic factor (recombinant)) Prescribing Information.2023Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines